12 June 2026 in Current Obesity Reports
Purposeof Review: Ghrelin is a gut-derived acylated hormone that regulates appetite, food reward-related behaviours, glycaemic control, and lipid metabolism. These actions are primarily mediated through activation of the growth hormone secretagogue receptor (GHSR), which is highly expressed in the brain and also present in key metabolic organs. Ghrelin acylation by ghrelin O -acyltransferase (GOAT) is required for receptor binding and biological activity. This review examines the physiological and pathophysiological roles of ghrelin and liver-expressed antimicrobial peptide 2 (LEAP2), with particular emphasis on its relevance to obesity and type 2 diabetes. Recent Findings: LEAP2 has recently been identified as an endogenous antagonist and inverse agonist of GHSR that counteracts ghrelin signalling. Emerging evidence indicates that obesity and type 2 diabetes are generally associated with reduced circulating ghrelin levels and increased LEAP2 concentrations, particularly in the presence of insulin resistance. These reciprocal changes support the concept that the ghrelin/LEAP2 ratio functions as a dynamic regulator of energy balance, glucose homeostasis, and appetite control, and may influence metabolic responses to nutritional status and weight loss. Summary: The ghrelin-LEAP2 system represents a key regulatory pathway in metabolic homeostasis and a promising therapeutic target for obesity and related metabolic disorders. Pharmacological strategies targeting this axis, including ghrelin antagonists, LEAP2 analogues, GOAT inhibitors, and GHSR inverse agonists, are under active investigation, although further studies are required to establish their long-term efficacy and safety.
23 March 2026 in Journal of Diabetes and its Complications
Ultrasound is a cost-effective tool for characterizing abdominal fat, with measurement accuracy comparable to advanced imaging techniques. A lack of standard operating procedures has hindered widespread adoption. Our study aimed to describe, through ultrasound, the adipose tissue layers of the abdominal wall in patients living with excess body fat. Cross-sectional study including 103 adults. Patients with a healthy fat mass were excluded. Fat mass was quantified through Clínica Universidad de Navarra-Body Adiposity Estimator (CUN-BAE). Ultrasound was performed at the midpoint between the xiphoid process and the navel (1-3 cm above the umbilicus) along the linea alba. Mean age (SD) was 46.6 (14.4) years, and 74.8% were women. A subcutaneous adipose tissue (SAT) measurement >1.8 cm showed significantly higher adiposity indices (BMI, CUN-BAE), systolic blood pressure, and laboratory metabolic parameters (insulin, HOMA-IR, triglycerides, creatinine) than those with SAT ≤1.8 cm. SAT was associated with an increased prevalence of dysglycemia (Q4 vs. Q1, adjusted OR 6.13; 95% CI 1.38-27.28), showing strong discriminative ability (AUC = 0.79; 95% CI 0.69-0.89). In a primary care setting, ultrasound characterization of abdominal fat should include measurement of the SAT maximum layer above the navel along the linea alba, as it may aid in evaluating metabolic risk.
25 November 2025 in Hormones
Background: Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy historically associated with a poor prognosis and a median survival of only 3.16 months. However, recent advances in molecular profiling and immunotherapy are improving outcomes. Case presentation: We report the case of a 68-year-old man diagnosed with stage IVC ATC who achieved sustained disease stabilisation and long-term survival. Initial treatment with chemotherapy and radiotherapy led to partial remission of the primary tumour, although there was progression of metastatic disease. The patient was subsequently enrolled in a clinical trial investigating an anti-PD-L1 antibody with positive test results, followed by treatment with pembrolizumab. The latter resulted in nearly 11 years of disease control without significant adverse effects, an exceptional outcome in the context of ATC. Conclusion: This case underscores the transformative potential of immunotherapy in the management of advanced ATC and highlights the importance of continued research into combinatorial therapeutic strategies and predictive biomarkers to optimise treatment outcomes.